NL-OMON39146已完成4 期
An Investigator Initiated, Controlled, Prospective, Non-Inferiority, Parallel-Group, randomised, Interventional, Open, Blinded Outcome Assessment (PROBE-Design), Multi-centre Trial, Comparing Efficacy and Safety of Isolation of the Pulmonary Veins with a Cryoballoon Catheter Versus a Radiofrequency Ablation with a ThermoCool Catheter in Patients with Paroxysmal Atrial Fibrillation - FIRE AND ICE Trial
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •DI1. Symptomatic PAF with at least two episodes within the last three months and at least one episode documented (30 seconds episode length).
- •I2. Documented treatment failure for effectiveness of at least one anti-arrhythmic drug (AAD Type I or III, excluding *-blocker and AAD intolerance).
- •I3. * 18 and * 75 years of age.
- •I4. Patients who are mentally and linguistically able to understand the aim of the trial and to show sufficient compliance in following the trial protocol.
- •I5. Patient is able to verbally acknowledge and understand the associated risks, benefits, and treatment alternatives to therapeutic options of this trial: cryoballoon ablation system or standard RF ablation technique. The patients, by providing informed consent, agree to these risks and benefits as stated in the patient informed consent document. All the details have been presented to him and he has signed the informed consent form for the trial.
排除标准
- •E1. Any disease that limits life expectancy to less than one year.
- •E2. Participation in another clinical trial (of a drug, device or biologic), either within the past two months or ongoing.
- •E3. Pregnant women or women of childbearing potential not on adequate birth control: only women with a highly effective method of contraception [oral contraception or intra-uterine device (IUD)] or sterile women can be randomised.
- •E4. Breastfeeding women.
- •E5. Substance misuse.
- •E6. Active systemic infection.
- •E7. Cryoglobulinaemia.
- •E8. Previous participation in this clinical trial.
- •E9. Patients with prosthetic valves.
- •E10. Employment by the sponsor or by the department of any of the investigators.
- •E11. Close relatives of any of the investigators.
- •E12. Any previous LA ablation or surgery.
- •E13. Any cardiac surgery or percutaneous coronary intervention (PCI) within three months prior to enrolment.
- •E14. Unstable angina pectoris.
- •E15. Myocardial infarction within three months prior to enrolment.
- •E16. Symptomatic carotid stenosis.
- •E17. Chronic obstructive pulmonary disease with detected pulmonary hypertension.
- •E18. Any condition contraindicating chronic anticoagulation.
- •E19 Stroke or transient ischemic attack within six months prior to enrolment.
- •E20. Any significant congenital heart defect corrected or not (including atrial septal defects or PV abnormalities) but not including patent foramen ovale.
- •E21. New York Heart Association (NYHA) class III or IV congestive heart failure.
- •E22. EF < 35 % (determined by echocardiography within 60 days of enrolment as documented in patient medical history).
- •E23. Anteroposterior LA diameter > 55 mm (by trans-thoracic echocardiography (TTE) within three months to prior enrolment).
- •E24. LA thrombus (TEE diagnostic performed on admission).
- •E25. Intracardiac thrombus.
- •E26. PV diameter > 26 mm in right sided PVs.
- •E27. Mitral prosthesis.
- •E28. Hyperthrophic cardiomyopathy.
- •E29. 2° (Type II) or 3° atrioventricular block.
- •E30. Brugada syndrome or long QT syndrome.
- •E31. Arrhythmogenic right ventricular dysplasia.
- •E32. Sarcoidosis.
- •E33. PV stent.
- •E34. Myxoma.
- •E35. Thrombocytosis (platelet count > 600,000 / µl), thrombocytopenia (platelet count < 100,000 / µl).
- •E36. Any untreated or uncontrolled hyperthyroidism or hypothyroidism.
- •E37. Severe renal dysfunction (stage V, requiring or almost requiring dialysis, glomerular filtration rate (GFR) < 15 ml / min).
研究者
相似试验
已完成
4 期
Feasibility and Efficacy of using a non-invasive pain numbing device in Australian Blood Donor Centres - Part 1Blood DonationACTRN12617000950369Australian Red Cross Blood Service50
终止
不适用
A randomised controlled trial of a non-invasive injection site desensitiser device for use in blood donation. Part 2: EfficacyBlood DonationACTRN12618000099224Australian Red Cross Blood Service450
招募中
不适用
A study investigating movement, pain and activity in failed back surgery patients undergoing spinal cord stimulation.Failed Back Surgery SyndromeLower back painLeg painMusculoskeletal - Other muscular and skeletal disordersNeurological - Other neurological disordersACTRN12615001038583Dr Richard Sullivan25
尚未招募
Unknown
This is a type of Prospective, Observational, Investigator-initiated Study (IIS) to Investigate the Real-World Effectiveness and Safety of Denosumab in Patients with Osteoporosis due to Chronic Kidney Disease.CTRI/2024/03/064791Dr Jatin Kothari
已完成
不适用
Prospective, randomized, controlled, Investigator Initiated Study to investigate Efficacy and Safety of cell-free Autologous Conditioned Serum (ACS) alone or in combination with hyaluronic acid (HA) in reduced facial skin elasticity by womareduce of facial skin elasticity in healthy volunteersDRKS00011249niversität Hamburg Fachrichtung Kosmetikwissenschaft42